RÉSUMÉ
BACKGROUND: The study was designed to investigate microvascular and morphological changes in retinal vein occlusion (RVO) using multimodal imaging after intravitreal ranibizumab (IVR) with or without triamcinolone acetonide (IVTA) injections. METHODS: This was a retrospective and observational study. Fifty patients (52 eyes) diagnosed with RVO were enrolled. Best corrected visual acuity (BCVA), ophthalmoscopy, fundus fluorescein angiography (FFA), spectral domain optical coherence tomography (SDOCT), and optical coherence tomography angiography (OCTA) were employed sequentially both before treatment and at the last visit after treatment. RESULTS: The mean logMAR VAs in BRVO eyes decreased significantly after treatment (P = 0.029). OCTA showed there was a significant difference in foveal avascular zone (FAZ) in BRVO eyes (P = 0.024), superificial foveal vessel density in both CRVO (P = 0.0004) and BRVO eyes (P = 0.02155). OCT showed the foveal thickness had significant differences after treatment in both CRVO (P < 0.0001) and BRVO eyes (P = 0.0001). BCVA was associated most commonly with ellipsoid zone integrity (P = 0.022). The BCVA in eyes treated with IVR and IVTA was significantly decreased compared with IVR only in BRVO group (P = 0.021). However, the combination of IVR + IVTA significantly improved intraocular pressure (IOP) compared with IVR only in BRVO group (P = 0.037). CONCLUSION: Both IVR and IVR + IVTA can significantly improve the central vision, macular structure, and functions in BRVO group. Simultaneous IVR with IVTA can significantly increase BCVA compared with IVR only in BRVO group.
Sujet(s)
Inhibiteurs de l'angiogenèse , Angiographie fluorescéinique , Glucocorticoïdes , Injections intravitréennes , Imagerie multimodale , Ranibizumab , Occlusion veineuse rétinienne , Tomographie par cohérence optique , Triamcinolone acétonide , Acuité visuelle , Humains , Occlusion veineuse rétinienne/traitement médicamenteux , Occlusion veineuse rétinienne/diagnostic , Occlusion veineuse rétinienne/physiopathologie , Études rétrospectives , Mâle , Triamcinolone acétonide/administration et posologie , Triamcinolone acétonide/usage thérapeutique , Femelle , Ranibizumab/administration et posologie , Ranibizumab/usage thérapeutique , Inhibiteurs de l'angiogenèse/usage thérapeutique , Inhibiteurs de l'angiogenèse/administration et posologie , Tomographie par cohérence optique/méthodes , Adulte d'âge moyen , Angiographie fluorescéinique/méthodes , Glucocorticoïdes/usage thérapeutique , Glucocorticoïdes/administration et posologie , Sujet âgé , Vaisseaux rétiniens/anatomopathologie , Vaisseaux rétiniens/imagerie diagnostique , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Association de médicamentsRÉSUMÉ
Loss of the inner blood-retinal barrier (BRB) integrity is a main feature of ocular diseases such as diabetic macular edema. However, there is a lack of clarity on how inner BRB function is modulated within the diabetic retina. The current study examined whether eucalyptol inhibited inner BRB destruction and aberrant retinal angiogenesis in 33 mM glucose-exposed human retinal microvascular endothelial (RVE) cells and db/db mice. This study further examined the molecular mechanisms underlying endothelial dysfunction including retinal endoplasmic reticulum (ER) stress and angiopoietin (Ang)/Tie axis in conjunction with vascular endothelial growth factor (VEGF). Eucalyptol is a naturally occurring monoterpenoid and an achiral aromatic component of many plants including eucalyptus leaves. Nontoxic eucalyptol reduced the production of amyloid-ß (Aß) protein in glucose-loaded RVE cells and in diabetic mice. This natural compound blocked apoptosis of Aß-exposed RVE cells in diabetic mouse eyes by targeting ER stress via the inhibition of PERK-eIF2α-ATF4-CHOP signaling. Eucalyptol promoted activation of the Ang-1/Tie-2 pathway and dual inhibition of Ang-2/VEGF in Aß-exposed RVE cells and in diabetic eyes. Supply of eucalyptol reversed the induction of junction proteins in glucose/Aß-exposed RVE cells within the retina and reduced permeability. In addition, oral administration of eucalyptol reduced vascular leaks in diabetic retinal vessels. Taken together, these findings clearly show that eucalyptol inhibits glucose-induced Aß-mediated ER stress and manipulates Ang signaling in diabetic retinal vessels, which ultimately blocks abnormal angiogenesis and loss of inner BRB integrity. Therefore, eucalyptol provides new treatment strategies for diabetes-associated RVE defects through modulating diverse therapeutic targets including ER stress, Ang-1/Tie-2 signaling, and Ang-2/VEGF.
Sujet(s)
Diabète expérimental , Rétinopathie diabétique , Stress du réticulum endoplasmique , Eucalyptol , Transduction du signal , Animaux , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Eucalyptol/pharmacologie , Souris , Rétinopathie diabétique/métabolisme , Rétinopathie diabétique/traitement médicamenteux , Rétinopathie diabétique/anatomopathologie , Transduction du signal/effets des médicaments et des substances chimiques , Humains , Diabète expérimental/métabolisme , Diabète expérimental/traitement médicamenteux , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Cellules endothéliales/métabolisme , Cellules endothéliales/effets des médicaments et des substances chimiques , Barrière hématorétinienne/métabolisme , Barrière hématorétinienne/effets des médicaments et des substances chimiques , Mâle , Apoptose/effets des médicaments et des substances chimiques , Angiopoïétine-1/métabolisme , Souris de lignée C57BL , Vaisseaux rétiniens/métabolisme , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Vaisseaux rétiniens/anatomopathologieRÉSUMÉ
PURPOSE: To study the effect of brimonidine on vascular density and flow index of optic nerve head (ONH) and macula in primary open angle glaucoma (POAG) using optical coherence tomography angiography (OCTA). METHODS: Twenty-three brimonidine-naïve POAG patients were started on brimonidine. They underwent OCTA ONH and macula before commencing brimonidine and one month thereafter. Systemic arterial blood pressure (SABP) and intraocular pressure (IOP) were measured at each visit to calculate mean ocular perfusion pressure (MOPP). The OCT angiograms were analyzed using ImageJ software to calculate ONH and macular flow indices. RESULTS: Thirty-seven eyes (23 patients) with a mean age of 56.7 ± 12.49 years were included of whom 60.8% were males. Brimonidine was associated with an increase in the superficial flow index (SFI) (P-value = 0.02) and optic nerve head flow index (ONHFI) (P-value = 0.01). Also, superficial vascular density (SVD) for whole image, superior-hemi and fovea increased (P-value = 0.03, 0.02, 0.03 respectively). ONH inferior-hemi vascular density decreased (P-value = 0.01) despite an increase in inferior quadrant retinal nerve fiber layer thickness (RNFLT) (P-value = 0.03). There was no statistically significant correlation between flow indices and MOPP at baseline and follow-up. A moderate negative correlation was found between SVD and DVD at the fovea and MOPP at baseline and follow-up (P-value = 0.03, 0.05) (P-value = 0.02, 0.01) respectively. CONCLUSIONS: Brimonidine was associated with an increase in SFI, ONHFI and SVD indicating improved GCC and RNFL perfusion in POAG. Despite the increase in inferior quadrant RNFLT, the concomitant decrease in inferior-hemi ONHVD precluded a conclusion of hemodynamically-mediated improvement of RNFLT.
Sujet(s)
Tartrate de brimonidine , Angiographie fluorescéinique , Glaucome à angle ouvert , Pression intraoculaire , Macula , Papille optique , Vaisseaux rétiniens , Tomographie par cohérence optique , Humains , Glaucome à angle ouvert/physiopathologie , Glaucome à angle ouvert/traitement médicamenteux , Glaucome à angle ouvert/diagnostic , Mâle , Papille optique/vascularisation , Tartrate de brimonidine/administration et posologie , Tartrate de brimonidine/pharmacologie , Tartrate de brimonidine/usage thérapeutique , Adulte d'âge moyen , Femelle , Tomographie par cohérence optique/méthodes , Macula/vascularisation , Macula/imagerie diagnostique , Pression intraoculaire/physiologie , Pression intraoculaire/effets des médicaments et des substances chimiques , Vaisseaux rétiniens/imagerie diagnostique , Vaisseaux rétiniens/physiopathologie , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Angiographie fluorescéinique/méthodes , Débit sanguin régional/physiologie , Débit sanguin régional/effets des médicaments et des substances chimiques , Sujet âgé , Fond de l'oeil , Études prospectives , Champs visuels/physiologie , Cellules ganglionnaires rétiniennes/anatomopathologie , Cellules ganglionnaires rétiniennes/effets des médicaments et des substances chimiques , Antihypertenseurs/usage thérapeutique , Neurofibres/anatomopathologie , Neurofibres/effets des médicaments et des substances chimiques , Adulte , Études de suiviRÉSUMÉ
BACKGROUND: Retinopathy of Prematurity (ROP) is a proliferative retinal vascular disease occurring in the retina of premature infants and is the main cause of childhood blindness. Nowadays anti-VEGF and retinal photocoagulation are mainstream treatments for ROP, but they develop a variety of complications. Hydrogen (H2) is widely considered as a useful neuroprotective and antioxidative therapeutic method for hypoxic-ischemic disease without toxic effects. However, whether H2 provides physiological angiogenesis promotion, neovascularization suppression and glial protection in the progression of ROP is largely unknown.This study aims to investigate the effects of H2 on retinal angiogenesis, neovascularization and neuroglial dysfunction in the retinas of oxygen-induced retinopathy (OIR) mice. METHODS: In this study, mice that were seven days old and either wild-type (WT) or Nrf2-deficient (Nrf2-/-) were exposed to 75% oxygen for 5 days and then returned to normal air conditions. Different stages of hydrogen gas (H2) inhalation were administered. Vascular obliteration, neovascularization, and blood vessel leakage were analyzed and compared. To count the number of neovascularization endothelial nuclei, routine HE staining of retinal sections was conducted. Immunohistochemistry was performed using DyLight 594 labeled GSL I-isolectin B4 (IB4), as well as primary antibodies against proliferating cell nuclear antigen (PCNA), glial fibrillary acidic protein (GFAP), and Iba-1. Western blots were used to measure the expression of NF-E2-related factor 2 (Nrf2), vascular endothelial growth factor (VEGF), Notch1, Dll4, and HIF-1α. Additionally, the expression of target genes such as NQO1, HO-1, Notch1, Hey1, Hey2, and Dll4 was measured. Human umbilical vein endothelial cells (HUVECs) treated with H2 under hypoxia were used as an in vitro model. RT-PCR was used to evaluate the mRNA expression of Nrf2, Notch/Dll4, and the target genes. The expression of reactive oxygen species (ROS) was observed using immunofluorescence staining. RESULTS: Our results indicate that 3-4% H2 does not disturb retinal physiological angiogenesis, but ameliorates vaso-obliteration and neovascularization in OIR mice. Moreover, H2 prevents the decreased density and reverses the morphologic and functional changes in retinal astrocytes caused by oxygen-induced injury. In addition, H2 inhalation reduces microglial activation, especially in the area of neovascularization in OIR mice. H2 plays a protective role in vascular regeneration by promoting Nrf2 activation and suppressing the Dll4-induced Notch signaling pathway in vivo. Also, H2 promotes the proliferation of HUVECs under hypoxia by negatively regulating the Dll4/Notch pathway and reducing ROS levels through Nrf2 pathway aligning with our findings in vivo.Moreover, the retinal oxygen-sensing mechanisms (HIF-1α/VEGF) are also involved in hydrogen-mediated retinal revascularization and neovascularization suppression. CONCLUSIONS: Collectively, our results indicate that H2 could be a promising therapeutic agent for POR treatment and that its beneficial effect in human ROP might involve the activation of the Nrf2-Notch axis as well as HIF-1α/VEGF pathways.
Sujet(s)
Modèles animaux de maladie humaine , Hydrogène , Névroglie , Oxygène , Néovascularisation rétinienne , Rétinopathie du prématuré , Animaux , Hydrogène/pharmacologie , Néovascularisation rétinienne/traitement médicamenteux , Névroglie/effets des médicaments et des substances chimiques , Souris , Rétinopathie du prématuré/traitement médicamenteux , Souris de lignée C57BL , Rétine/effets des médicaments et des substances chimiques , Animaux nouveau-nés , Régénération/effets des médicaments et des substances chimiques , Immunohistochimie , Vaisseaux rétiniens/effets des médicaments et des substances chimiquesRÉSUMÉ
Purpose: To compare changes in superficial retinal vascular density (SRVD), deep retinal vascular density (DRVD), and retinal thickness (RT) of the macular zone after repeated low-level red light (RLRL) and 0.01% atropine exposure in premyopic schoolchildren. Methods: Prospective randomized trial. Sixty-nine schoolchildren with cycloplegic refraction >-0.75 D and ≤0.50 D were randomly assigned to RLRL and 0.01% atropine groups. SRVD, DRVD, and RT were measured using swept-source optical coherence tomography at baseline and six months. The macular zone was divided into three concentric rings (fovea, parafovea, and perifovea) using the Early Treatment Diabetic Retinopathy Study. Results: After six months, the whole, parafoveal, and perifoveal SRVD significantly increased in the two groups (all P < 0.05). Multivariate regression analyses showed that none of these changes varied significantly between the two groups (all P > 0.05), whereas foveal SRVD remained stable in both groups (all P > 0.05). In the RLRL group, the whole and perifoveal DRVD increased significantly (all P < 0.05), whereas no statistical difference was observed in the foveal and parafoveal DRVD. DRVD remained stable in the 0.01% atropine group (all P > 0.05). No significant differences were observed in RT changes between the two groups (all P > 0.05). In comparison, there were no significant changes in SRVD, DRVD, or RT after six months in the placebo group in our previous study. Conclusions: SRVD increased similarly in the RLRL and 0.01% atropine groups, whereas DRVD increased only in the former group. There were no significant RT changes in either group after six months of treatment in premyopic schoolchildren. Translational Relevance: This research observed the effects of low-level red light and 0.01% atropine on retinal vasculature, offering valuable insights into myopia progression prevention.
Sujet(s)
Atropine , Mydriatiques , Vaisseaux rétiniens , Tomographie par cohérence optique , Humains , Atropine/administration et posologie , Atropine/pharmacologie , Mâle , Femelle , Enfant , Études prospectives , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Vaisseaux rétiniens/imagerie diagnostique , Mydriatiques/administration et posologie , Mydriatiques/pharmacologie , Myopie/traitement médicamenteux , Myopie/anatomopathologie , Solutions ophtalmiques/administration et posologie , Solutions ophtalmiques/usage thérapeutique , Photothérapie/méthodes , Densité microvasculaire/effets des médicaments et des substances chimiques ,RÉSUMÉ
To investigate the effects and molecular mechanisms of wedelolactone (WEL) on high glucose-induced injury of human retinal vascular endothelial cells (HRECs). The cell injury model was established by incubating HRECs with 30 mmol/L glucose for 24 hour. HRECs were divided into control (Con) group, high glucose (HG) group, HGâ +â WEL-low dose (L) group, HGâ +â WEL-medium dose (M), HGâ +â WEL-high dose (H) group, HGâ +â miR-NC group, HGâ +â miR-190 group, HGâ +â WELâ +â antimiR-NC group, HGâ +â WELâ +â antimiR-190 group. The kit detects cellular reactive oxygen species (ROS), superoxide dismutase (SOD), and malondialdehyde (MDA) content; cell apoptosis was analyzed by flow cytometry; miR-190 expression was detected by real-time quantitative PCR (RT-qPCR). Compared with Con group, the levels of ROS and MDA in the HG group were significantly increased (Pâ <â .01), the SOD activity and the expression of miR-190 expression were significantly decreased (Pâ <â .05), and the apoptosis rate was significantly increased (Pâ <â .01). Compared with HG group, the levels of ROS and MDA in HGâ +â WEL-L group, HGâ +â WEL-M group and HGâ +â WEL-H group were significantly decreased (Pâ <â .05), SOD activity and miR-190 expression were significantly increased (Pâ <â .05), and apoptosis rate was significantly reduced (Pâ <â .05). Compared with the HGâ +â miR-NC group, the levels of ROS and MDA in HGâ +â miR-190 group were significantly reduced (Pâ <â .01), SOD activity was significantly increased (Pâ <â .01), and apoptosis rate was significantly reduced (Pâ <â .05). Compared with the HGâ +â WELâ +â antimiR-NC group, the ROS level and MDA content in the HGâ +â WELâ +â antimiR-190 group were significantly increased (Pâ <â .05), SOD activity was significantly decreased (Pâ <â .05), and apoptosis rate was significantly increased (Pâ <â .05). Wedelolactone can attenuate high glucose-induced HRECs apoptosis and oxidative stress by up-regulating miR-190 expression.
Sujet(s)
Apoptose , Coumarines , Cellules endothéliales , Glucose , microARN , Espèces réactives de l'oxygène , Humains , microARN/métabolisme , Apoptose/effets des médicaments et des substances chimiques , Espèces réactives de l'oxygène/métabolisme , Cellules endothéliales/effets des médicaments et des substances chimiques , Cellules endothéliales/métabolisme , Coumarines/pharmacologie , Superoxide dismutase/métabolisme , Malonaldéhyde/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Vaisseaux rétiniens/métabolisme , Cellules cultivéesSujet(s)
COVID-19 , Glucocorticoïdes , Microcirculation , Vaisseaux rétiniens , Humains , Microcirculation/effets des médicaments et des substances chimiques , COVID-19/complications , Glucocorticoïdes/usage thérapeutique , Glucocorticoïdes/effets indésirables , Mâle , Femelle , Adulte d'âge moyen , Vaisseaux rétiniens/anatomopathologie , Vaisseaux rétiniens/imagerie diagnostique , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , SARS-CoV-2 , Sujet âgé , Traitements médicamenteux de la COVID-19 , Rétine/anatomopathologieRÉSUMÉ
The early pathogenetic mechanism of diabetic retinopathy (DR) and its treatment remain unclear. Therefore, we used streptozotocin-induced diabetic mice to investigate the early pathogenic alterations in DR and the protective effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors against these alterations. Retinal vascular leakage was assessed by dextran fluorescence angiography. Retinal thickness and vascular leakage were increased 2 and 4 weeks after onset of diabetes, respectively. Immunostaining showed that morphological change of microglia (amoeboid form) was observed at 2 weeks. Subsequently, increased angiopoietin-2 expression, simultaneous loss of pericytes and endothelial cells, decreased vessel density, retinal hypoxia, and increased vascular endothelial growth factor (VEGF)-A/VEGF receptor system occurred at 4 weeks. SGLT2 inhibitors (luseogliflozin and ipragliflozin) had a significant protective effect on retinal vascular leakage and retinal thickness at a low dose that did not show glucose-lowering effects. Furthermore, both inhibitors at this dose attenuated microglia morphological changes and these early pathogenic alterations in DR. In vitro study showed both inhibitors attenuated the lipopolysaccharide-induced activation of primary microglia, along with morphological changes toward an inactive form, suggesting the direct inhibitory effect of SGLT2 inhibitors on microglia. In summary, SGLT2 inhibitors may directly prevent early pathogenic mechanisms, thereby potentially playing a role in preventing DR.
Sujet(s)
Diabète expérimental , Rétinopathie diabétique , Microglie , Inhibiteurs du cotransporteur sodium-glucose de type 2 , Animaux , Rétinopathie diabétique/métabolisme , Rétinopathie diabétique/anatomopathologie , Rétinopathie diabétique/traitement médicamenteux , Inhibiteurs du cotransporteur sodium-glucose de type 2/pharmacologie , Inhibiteurs du cotransporteur sodium-glucose de type 2/usage thérapeutique , Souris , Microglie/effets des médicaments et des substances chimiques , Microglie/métabolisme , Microglie/anatomopathologie , Diabète expérimental/métabolisme , Diabète expérimental/traitement médicamenteux , Mâle , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Facteur de croissance endothéliale vasculaire de type A/antagonistes et inhibiteurs , Rétine/anatomopathologie , Rétine/effets des médicaments et des substances chimiques , Rétine/métabolisme , Souris de lignée C57BL , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Vaisseaux rétiniens/anatomopathologie , Vaisseaux rétiniens/métabolisme , Thiophènes/pharmacologie , Thiophènes/usage thérapeutique , Angiopoïétine-2/métabolisme , Angiopoïétine-2/antagonistes et inhibiteursRÉSUMÉ
Introducción y objetivos Investigar el efecto de la acetazolamida (AZ) sobre la microvasculatura ocular retiniana y coroidea en la mácula y los capilares peripapilares radiales (CPR) del disco óptico con angiografía-OCT (OCTA). Materiales y métodos Estudio transversal observacional de 9meses de duración. Se reclutaron 45 ojos de 45 participantes sanos que se sometieron a cirugía de cataratas. Se comparó la densidad de vasos (DV) de la retina macular y la coriocapilar (CC) y la DV de la CPR en la zona del disco óptico antes y 60 min después de administrar 250mg de AZ por vía oral. También se midieron la presión intraocular (PIO) y la presión arterial (PA) sistémica antes de cada exploración. Resultado La edad media era de 73,1±6,9 años. La densidad de vasos (DV) en el plexo capilar superficial (PCS) y profundo (PCP) de la retina y la CC en el área macular no mostraron cambios significativos (p>0,5, para todos los parámetros). La DV en los CPR no mostró cambios significativos con la AZ (p>0,5, para todos los parámetros). El grosor foveal y parafoveal aumentó de 248,98 (± 23,89) a 250,33 (± 23,74) y de 311,62 (± 16,53) a 311,98 (± 16,38) (p<0,001 y p=0,046), respectivamente. La PIO disminuyó de 13,2 (± 3,0) mmHg a 11,8 (± 3,2) mmHg (p<0,001), mientras que la PA sistólica y diastólica disminuyó de 144,8 (± 21,8) a 137,7 (± 19,0) y de 80,0 (± 12,7) a 76,2 (± 11,7) (p=0,021 y p=0,030), respectivamente. Conclusiones Las imágenes de OCTA no revelaron cambios significativos en la VD del disco óptico ni en el VD de la retina y la coroides en la mácula con AZ oral una hora después de su administración en participantes por lo demás sanos que se sometieron a cirugía de cataratas (AU)
Introduction and objectives To investigate the effect of acetazolamide (AZ) on the retinal and choroidal ocular microvasculature in the macula and radial peripapillary capillaries (RPC) of the optic disc with OCT Angiography (OCTA). Materials and method Nine-month observational cross-sectional study. Forty-five eyes from 45 healthy participants who underwent cataract surgery were recruited. Macular retina and choriocapillaris vessel density (VD) and RPC VD in the optic disc area were compared before and 60minutes after 250mg acetazolamide per os. Intraocular pressure (IOP) and systemic blood pressure (BP) were also measured before each scan. Result Mean age was 73.1±6.9 years. VDs in the superficial (SCP) and deep (DCP) capillary plexus of the retina and the choriocapillaris (CC) in the macular area showed no significant change (p>0.5, for all parameters). VD in the RPC showed no significant change with AZ (p>0.5, for all parameters). Foveal and parafoveal thickness increased from 248.98 (±23.89) to 250.33 (±23.74) and from 311.62 (±16.53) to 311.98 (±16.38) (p<0.001 and p=0.046), respectively. IOP decreased from 13.2 (±3.0) mmHg to 11.8 (±3.2) mmHg (p<0.001), while systolic and diastolic BP decreased from 144.8 (±21.8) to 137.7 (±19.0) and from 80.0 (±12.7) to 76.2 (±11.7) (p=0.021 and p=0.030), respectively. Conclusion OCTA imaging did not reveal any significant changes in the VD of the optic disc or the retinal and choroidal VD in the macula with oral AZ one hour after its administration in otherwise healthy participants who underwent cataract surgery (AU)
Sujet(s)
Humains , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Sujet âgé de 80 ans ou plus , Acétazolamide/pharmacologie , Inhibiteurs de l'anhydrase carbonique/pharmacologie , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Papille optique/effets des médicaments et des substances chimiques , Choroïde/effets des médicaments et des substances chimiques , Études transversales , Tomographie par cohérence optique , Angiographie par tomodensitométrie , Vaisseaux rétiniens/imagerie diagnostique , Papille optique/imagerie diagnostique , Choroïde/imagerie diagnostiqueRÉSUMÉ
Abstract Purpose: To investigated the effects of ginsenoside Rb1 on diabetic retinopathy in streptozotocin-induced diabetic rats. Methods: Diabetes was induced by a single intraperitoneal injection of streptozotocin (80 mg/kg) in male Wistar rats. Ginsenoside Rb1 (20, 40 mg/kg) was injected (i.p.) once a day for 4 weeks. Then, using fundus photography, the diameter and vascular permeability of retinal vessels were investigated. Retinal histopathology was undertaken. Contents of malondialdehyde (MDA) and glutathione (GSH) in retinas were assayed. Levels of nuclear factor erythroid 2-related factor 2 (Nrf2), glutathione cysteine ligase catalytic subunit (GCLC), and glutathione cysteine ligase modulatory subunit (GCLM) were measured. Results: Treatment with ginsenoside Rb1 attenuated the diabetes-induced increase in the diameter of retinal blood vessels. Ginsenoside Rb1 reduced extravasation of Evans Blue dye from retinal blood vessels. Ginsenoside Rb1 partially inhibited the increase in MDA content and decrease in GSH level in rat retinas. Nrf2 levels in the nuclei of retinal cells and expression of GCLC and GCLM were increased significantly in rats treated with ginsenoside Rb1. Conclusion: These findings suggest that ginsenoside Rb1 can attenuate diabetic retinopathy by regulating the antioxidative function in rat retinas.
Sujet(s)
Animaux , Mâle , Rats , Diabète expérimental/traitement médicamenteux , Rétinopathie diabétique/traitement médicamenteux , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Vaisseaux rétiniens/anatomopathologie , Rat Wistar , Streptozocine , Ginsénosides/usage thérapeutiqueRÉSUMÉ
Photodynamic therapy (PDT) involves the induction of endothelial cell death or occlusion of blood vessels. On the basis of this mechanism of action, PDT is used in the treatment of predominant classic choroidal neovascularization (CNV), if the classic component is over 50%, and in myopic CNV. This study describes 2 cases of distinctive, abnormal, large, subretinal new vessels that are thought to have originated from the choroids. Diminishment of the new vessels was observed following treatment with PDT.
Sujet(s)
Adulte d'âge moyen , Mâle , Humains , Femelle , Vaisseaux rétiniens/effets des médicaments et des substances chimiques , Rétinopathies/traitement médicamenteux , Photothérapie dynamique , Néovascularisation pathologique/traitement médicamenteux , AngiographieRÉSUMÉ
Relato de caso de um paciente com telangiectasia justafoveal idiopática (TJI) tipo 1A, no olho direito, submetido a 4 mg de triancinolona intravítrea. O resultado foi avaliado por meio da acuidade visual e da tomografia de coerência óptica. A acuidade visual e a espessura retiniana macular medida na tomografia de coerência óptica, antes da injeção intravítrea de triancinolona, foram respectivamente de 20/100 e 569 æm e, após três semanas do tratamento foram de 20/60 e 371 æm e na sexta semana de 20/100 e 614 æm. A estabilização da parede vascular obtida com injeção intravítrea de triancinolona proporciona melhora transitória da visão e do edema macular em olhos com TJI-1A. Não foi demonstrada nenhuma ajuda permanente à fotocoagulação prévia.
Case report of one idiopathic juxtafoveal telangiectasis (IJT) 1A patient whose right eye was treated with a 4 mg intravitreal triamcinolone acetonide injection. The outcome was evaluated by visual acuity and optic coherence tomography. The visual acuity and the caliper retinal thickness before triamcinolone injection were respectively 20/100 and 569 æm, and 20/60 and 371 æm after three weeks and 20/100 and 614 æm after six week of follow-up. The stabilization of the vascular wall due to the intravitreal triamcinolone injection leads to a transitory improvement in vision and reduction in macular edema in the TJI 1A eyes. No permanent help by the photocoagulation could be shown.